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httpcense.Abstract Background: Thyroid dysfunction or non-thyroidal illness syndrome (NTIS) is fre-
quently detected in chronic, systemic diseases. The systemic manifestations of chronic obstructive
pulmonary disease (COPD) include a number of endocrine disorders. The severity of hypoxia
and airway obstruction in COPD patients might cause alterations in thyroid function.
The aim of this study is to assess serum levels of thyroid hormones and the inﬂammatory bio-
markers; IL-6, TNF-a in COPD patients during stability and acute exacerbation of the disease,
and also to assess the relation between severity of COPD and levels of thyroid hormones.
Subjects and methods: Forty stable COPD patients and twenty COPD patients with acute exac-
erbation were included in this study as patient groups and twenty healthy age-matched non smoker
subjects with normal pulmonary function as a control group. The diagnosis of COPD and acute
exacerbation of COPD were established according to GOLD (2011) criteria. Stable COPD patients
were further subdivided into Mild-to-moderate COPD patient group (FEV1P 50% of predicted
value, which included 14 patients) and Severe COPD patient group (FEV1 < 50% of predicted
value, which included 26 patients). All enrolled patients were subjected to measurements of pulmon-
ary function tests (FEV1%, FVC% and FEV1/FVC ratio), arterial blood gases (ABGs) (PaO2,
PaCO2, pH), serum levels of thyroid hormones (TSH, total T3, total T4, free T3 and free T4)
and the inﬂammatory biomarkers IL-6 and TNF-a on the ﬁrst day of admission to RICU or ﬁrst
visit to the outpatient clinics.01004540265.
com (A. Shoukry).
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568 A. Shoukry et al.Results: There was a signiﬁcant decrease in serum total T3 and free T3 levels in stable COPD
patients when compared to control subjects. Also, there was a signiﬁcant decrease in serum total
T3, free T3, TSH levels and TT3/TT4 ratio in the COPD exacerbation patient group when com-
pared to control subjects and when compared to stable COPD patients. There were no statistically
signiﬁcant differences in serum levels of total T4, free T4 between the studied groups. Regarding
disease severity, serum total T3, free T3 levels and TT3/TT4 ratio were signiﬁcantly decreased in
severe COPD patients when compared to mild-to-moderate COPD patients. There were signiﬁcant
positive correlations between PaO2 and both serum total T3 and TT3/TT4 ratio in the stable COPD
group. Serum IL-6 and TNF-a levels were signiﬁcantly increased in both stable and exacerbation
phase COPD patient groups when compared to control subjects.
Conclusion: COPD is a systemic disease that may produce signiﬁcant alterations in serum levels
of thyroid hormones, especially in severe COPD patients and during exacerbation phases of COPD
where NTIS is more evident. There was a signiﬁcant decrease in serum total T3 and free T3 levels in
stable COPD patients and this decrease was more signiﬁcantly evident with a superadded signiﬁcant
decrease in serum TSH levels during the exacerbation phase of COPD. The hormonal alterations
are especially related to severity of the disease and hypoxemia. Serum IL-6 and TNF-a levels were
increased even in stable COPD and this rise is magniﬁed with increased disease severity and during
exacerbation phases of COPD.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V.Open access under CC BY-NC-ND license.Introduction
Chronic obstructive pulmonary disease (COPD) is associated
with low grade systemic inﬂammation that may be responsible
for the systemic effects of the disease; malnutrition, muscle
wasting, osteoporosis, cardiovascular disease, type II diabetes
mellitus, anemia and depression [1]. COPD is no longer con-
sidered to affect only the lungs and airways but also the rest
of the body. The systemic manifestations of COPD include a
number of endocrine disorders such as those involving the
pituitary, thyroid, gonads, adrenals and pancreas [2]. The thy-
roid hormone enhances mitochondrial oxidation, and thus,
augments metabolic rate .This effect on metabolic rate is prob-
ably responsible for the association between the thyroid hor-
mone and respiratory drive [3]. The terms ‘‘Non-thyroidal
Illness Syndrome (NTIS)’’ and ‘‘Euthyroid Sick Syndrome
(ESS)’’ have been used to describe alterations in thyroid func-
tion tests in critical illness, such as starvation, sepsis, surgery,
myocardial infarction, and also in chronic, systemic diseases
including chronic heart failure, chronic liver or hematologic
diseases, cancer, diabetes, connective tissue diseases and
COPD [4]. Proinﬂammatory cytokines, especially IL-6, IL-
1b, TNF-a and IFN-c have inhibiting effects on peripheral
thyroid hormone metabolism [5,6].These mediators may also
be involved in the pathogenesis of NTIS [4].
Limited data on the prevalence of thyroid diseases among
patients with COPD are available [4,7], yet, several character-
istics of patients with COPD could potentially increase their
likelihood of developing hypothyroidism and hyperthyroidism
[2]. Also the severity of airway obstruction in these patients is
associated with impairment of thyroid gland function [8].
The aim of this study is to assess serum levels of thyroid
hormones and the inﬂammatory biomarkers IL-6 and TNF-a
in COPD patients during stability and acute exacerbation of
the disease, and also to assess the relation between the severity
of COPD and levels of thyroid hormones.Subjects and methods
This cross-sectional prospective study was conducted between
October 2011 and February 2013 at Internal medicine, Chest
and Medical Biochemistry Departments, Zagazig University
Hospitals.
This study comprised 40 stable COPD patients and 20
COPD patients with acute exacerbation as patient groups
and 20 healthy non smoker age-matched subjects with normal
pulmonary function as a control group.
Stable COPD Patients (had been clinically stable for at
least 3 months) were recruited from the outpatient clinics of
Chest and Internal Medicine Departments. Patients with
acute exacerbation of COPD (had clinical signs of COPD
exacerbation as increased dyspnea, increased cough and spu-
tum, wheezing and chest tightness, fever. tachycardia and
tachypnea) were admitted to the respiratory intensive care
unit (RICU). In both patient groups, all males were ex-smok-
ers, but females were non smokers. The diagnosis and acute
exacerbation of COPD were established according to Global
Initiative for Chronic Obstructive Lung Disease (GOLD
2011) criteria [9].
Spirometric classiﬁcation of disease severity in stable
COPD patients (Stage I ‘‘mild’’, Stage II ‘‘moderate’’, Stage
III ‘‘severe’’ and Stage IV ‘‘very severe’’) was done according
to GOLD criteria [9].
Stable COPD patients were further subdivided into Mild-
to-moderate COPD patient group (Stage I and Stage II,
FEV1P 50% of predicted value, n= 14) and Severe COPD
patient group (Stage III and Stage IV, FEV1 < 50% of pre-
dicted value, n= 26).
Stable COPD patients had been receiving inhaled broncho-
dilator therapy in the form of long-acting b2-agonists and/or
anticholinergic agents. Severe/very severe COPD patients were
on inhaled corticosteroids.
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Patients on systemic glucocorticoid therapy or who use drugs
known to affect thyroid function such as amiodarone or io-
dine-containing contrast media. Patients with clinical evidence
of thyroid disease (hypo/or hyperthyroidism) or coexistence of
other diseases altering thyroid function tests. Pituitary hypo-
thalamic disease, sepsis, malignancy, signiﬁcant cardiac, renal,
hepatic, metabolic or endocrine disturbances were excluded.
All subjects gave written informed consent to participate in
the study.
All enrolled individuals were subjected to the following:
1 – Thorough medical history and full clinical examination.
Anthropometric measurements were taken and body
mass index (BMI) was calculated as weight/height2
(kg/m2).
2 – Plain chest X-ray (postero-anterior and lateral views).
3 – Routine laboratory investigations (CBC, liver and kid-
ney functions).
4 – Pulmonary function tests: were done on the ﬁrst day of
admission or in the outpatient clinic for stable COPD
patients. Forced expiratory volume in one second
(FEV1) and forced vital capacity (FVC) were measured
with ZAN-100 Flow Handy P Pulmonary Function
Apparatus. patients with FEV1P 80% of predicted
value were considered mild, those with
50% 6 FEV1 < 80% of predicted value were consid-
ered moderate, those with 30% 6 FEV1 < 50% of pre-
dicted value were considered severe and patients with
FEV1 < 30% of predicted value were considered very
severe [9].
5 – Arterial blood gases (ABG) analysis: was done on the
ﬁrst day of admission or in the outpatient clinic for sta-
ble COPD patients to check arterial oxygen tension
(PaO2), arterial carbon dioxide tension (PaCO2) and
arterial pH. Arterial blood samples were drawn while
the subjects were breathing room air and analyzed
immediately using a blood gas analyzer (ABL-330-
Radiometer Copenhagen).
6 – Thyroid hormones measurement: serum levels of total tri-
iodothyronine (total T3), Total thyroxine (total T4), free
triiodothyronine (free T3), free thyroxine (free T4) and
thyroid stimulating hormone (TSH) were determined
by using the commercial Roche Elecsys reagent kits
(Roche Diagnostica USA), Measurements were per-
formed using the Chemiluminescence method by
COBAS E 411 Roche Hitashi Apparatus. The ratio of
TT3/TT4 was calculated. (Reference values for thyroid
function tests: TSH: 0.27–4.2 lIU/ml; total T3: 0.8–
2.0 ng/ml; total T4: 5.1–14.1 lg/dl; free T3: 2.0–4.4 pg/
ml; free T4: 0.93–1.7 ng/dl).
7 – Interleukin 6 (IL6) and Tumor necrosis factor-alpha
(TNF-a) measurement: serum TNF-a was measured
by a solid phase sandwich enzyme-linked immunosor-
bent assay (ELISA) using hTNF-a kit (BioSource Inter-
national Inc., CA, USA).
Serum IL-6 was measured with enzyme-linked immunosor-
bent assay (ELISA) kits (Biosource International Inc., CA,
USA).For patients, blood samples were collected at the ﬁrst day
of RICU admission (for COPD exacerbation patients) or in
the outpatient clinic (for stable COPD patients). After centri-
fugation, sera were kept frozen at 80 C until assayed.
Statistical analysis
Statistical analysis of the results was performed using SPSS
software version 16.0 (statistical package for social science,
SPSS inc. Chicago, USA). Continuous variables were ex-
pressed as means ± standard deviation (SD). Comparison
between two sets of patients was performed by unpaired Stu-
dent’s t test, but more than two sets of patients were com-
pared by one-way ANOVA. Categorical variables were
expressed as percent, and compared by chi-square (v2) test.
Correlation coefﬁcient ‘‘r’’ was used to describe the associa-
tion between serum levels of thyroid hormones and the vari-
ables of interest. p Values <0.05 were considered statistically
signiﬁcant.
Results
Demographic characteristics, pulmonary function tests and
arterial blood gases analysis of stable and exacerbation per-
iod COPD patients and control subjects enrolled in the
study are shown in Table 1.
Age, gender and BMI were not found to be statistically dif-
ferent between the studied groups. There was a statistically sig-
niﬁcant difference in FEV1% of predicted, FVC% of
predicted, FEV1/FVC, PaO2 and PaCO2 between stable
COPD patients, COPD patients with acute exacerbation and
control subjects.
Serum thyroid hormones, IL6 and TNF-a levels of stable
and exacerbation period COPD patients and control sub-
jects are shown in Table 2.
Mean serum levels of total T3 and free T3 were signiﬁcantly
lower in stable COPD patients when compared to control sub-
jects (p= 0.01, p= 0.004, respectively), whereas there were no
statistically signiﬁcant differences in mean serum levels of total
T4, free T4 and TSH between the two groups.
In the COPD exacerbation group, mean serum levels of to-
tal T3, free T3 and TSH were found to be signiﬁcantly lower
when compared to control subjects (p< 0.001, p< 0.001,
p= 0.002, respectively), but levels of total T4 and free T4
did not differ signiﬁcantly between the two groups.
When stable and exacerbation COPD groups were com-
pared, serum levels of total T3, free T3 and TSH were found
to be signiﬁcantly lower in exacerbation COPD patients
(p= 0.001, p< 0.001, p< 0.001, respectively), TT3/TT4 ra-
tio was signiﬁcantly decreased in the COPD exacerbation
group when compared to control subjects (p= 0.02) and also
when compared to stable COPD patients (p= 0.04), but did
not differ signiﬁcantly between stable COPD and control
groups.
Serum IL-6 and TNF-a levels were signiﬁcantly higher in
both stable (p= 0.02, p= 0.01, respectively), and exacerba-
tion phase (p= 0.007, p< 0.001, respectively) COPD patient
groups than control subjects.
Table 1 Demographic characteristics, pulmonary function tests and arterial blood gases analysis of the studied groups.
Stable COPD
No. 40
COPD Exacerbation
No. 20
Control Subjects
No. 20
*p **p ***p
Age (years) 54.5 ± 7.6 56.8 ± 8.3 53.6 ± 8.2 0.67 0.22 0.28
Sex
Male 35 87.5% 18 90% 17 85% 0.9 1.0 0.9
Female 5 12.5% 2 10% 3 15%
BMI (Kg/m2) 24.8 ± 3.4 25.2 ± 2.5 24.3 ± 1.58 0.44 0.18 0.64
Pulmonary functions
FEV1 (% predicted) 54.8 ± 14.5 44.6 ± 11.9 94.7 ± 12.6 <0.001 <0.001 0.009
FVC (% predicted) 84.6 ± 23.4 51.9 ± 12.7 97.3 ± 14.5 0.03 <0.001 <0.001
FEV1/FVC 53.5 ± 13.8 43.5 ± 12.7 86.4 ± 6.7 <0.001 <0.001 0.009
Arterial blood gases
pH 7.4 ± 0.06 7.32 ± 0.08 7.38 ± 0.04 0.19 0.005 <0.001
PaO2 mmHg 67.2 ± 14.5 51.4 ± 8.2 94.5 ± 6.9 <0.001 <0.001 <0.001
PaCO2 mmHg 45.8 ± 11.6 59.3 ± 12.4 38.3 ± 2.9 0.006 <0.001 <0.001
* p-Value is obtained by comparison of Stable COPD patients and control subjects.
** p-Value is obtained by comparison of COPD exacerbation patients and control subjects.
*** p-Value is obtained by comparison of Stable COPD and COPD exacerbation patients.
Table 2 Thyroid hormones, IL6 and TNF-a of the studied groups.
Stable COPD No. 40 COPD Exacerbation No. 20 Control Subjects No. 20 *p **p ***p
TSH (lIU/ml) 1.6 ± 0.9 0.61 ± 0.48 1.18 ± 0.6 0.65 0.002 <0.001
Total T3 (ng/ml) 1.03 ± 0.22 0.78 ± 0.35 1.2 ± 0.26 0.01 <0.001 0.001
Total T4 (lg/dl) 8.58 ± 1.6 8.6 ± 1.4 8.57 ± 1.5 0.98 0.95 0.96
Free T3 (pg/ml) 2.44 ± 0.65 1.82 ± 0.48 2.98 ± 0.68 0.004 <0.001 <0.001
Free T4 (ng/dl) 1.17 ± 0.24 1.28 ± 0.48 1.14 ± 0.32 0.69 0.29 0.34
TT3/TT4 ratio 0.12 ± 0.06 0.09 ± 0.03 0.14 ± 0.09 0.31 0.02 0.04
IL6 (pg/ml) 63.87 ± 59.42 72.57 ± 61.37 29.7 ± 26.2 0.02 0.007 0.59
TNF-a (pg/ml) 11.34 ± 9.82 19.4 ± 16.43 5.33 ± 4.32 0.01 <0.001 0.02
* p-Value is obtained by comparison of stable COPD patients and control subjects.
** p-Value is obtained by comparison of COPD exacerbation patients and control subjects.
*** p-Value is obtained by comparison of stable COPD and COPD exacerbation patients.
570 A. Shoukry et al.Also, there was a signiﬁcant increase in serum TNF-a level in
exacerbation phase COPD patients when compared to stable
COPD patient (p= 0.02) but the difference was statistically
non-signiﬁcant as regards serum IL-6 level between both groups.
Serum thyroid hormones, IL6 and TNF-a levels of mild-to-
moderate and severe stable COPD patients are given in
Table 3.
Levels of total T3 and free T3 and TT3/TT4 ratio were sig-
niﬁcantly lower in severe COPD patients compared to mild-to-
moderate COPD patients (p< 0.001, p< 0.001 and p= 0.03,
respectively), but the difference was statistically non-signiﬁcant
as regards serum total T4, free T4 and TSH levels between
both groups.
Also,therewasasigniﬁcantincreaseinserumTNF-alevelinse-
vereCOPDpatientswhencomparedtomild-to-moderateCOPD
patients (p= 0.006), but the difference was statistically non-sig-
niﬁcant as regards serumIL-6 level betweenbothgroups.
Correlation tests between serum levels of thyroid hormones
(TSH, total T3. total T4 free T3 and free T4) and FEV1% pre-
dicted, PaO2, PaCO2, IL-6 and TNF-a were made in stable
and exacerbation phase COPD patients. In the stable COPD
group, there was a signiﬁcant positive correlation betweenTT3/TT4 ratio and PaO2 (r= 0.92; p< 0.001). Similarly
serum total T3 levels also showed a signiﬁcant positive corre-
lation with PaO2 (r= 0.76; p< 0.001) {Figs. 1 and 2}. No
other correlations were found between serum levels of thyroid
hormones and these various variables in both stable and exac-
erbation phase COPD patient groups.
Discussion
The non-thyroidal illness syndrome, also known as euthyroid
sick syndrome, describes a condition characterized by abnor-
mal plasma levels of thyroid hormones encountered in patients
with a variety of acute or chronic systemic illnesses [10,11].
Several conditions are described, the most important of which
is the low T3 syndrome [12], which is characterized by reduced
plasma levels of triiodothyronine (T3) due to impaired activity
of speciﬁc 50 monodeiodinases converting thyroxine (T4) to T3
in peripheral tissues, with normal or low levels of T4 and either
normal or slightly suppressed thyroid-stimulating hormone
(TSH) levels [11,13]. The changes in serum thyroid hormone
levels in the critically ill patient seem to result from alterations
in the peripheral metabolism of the thyroid hormones, in TSH
regulation, in the binding of thyroid hormone to transport-
proteins and in receptor binding and intracellular uptake.
Table 3 Pulmonary functions, arterial blood gases, thyroid hormones and IL6 and TNF-a of Mild-to-moderate and Severe COPD
patients.
Mild-to-moderate COPD No. 14 Severe COPD No. 26 p-Value
FEV1 (% predicted) 64.72 ± 9.38 45.82 ± 7.63 <0.001
FEV1/FVC 60.43 ± 8.52 46.53 ± 9.45 <0.001
PaO2 mmHg 78.32 ± 6.42 55.85 ± 7.93 <0.001
PaCO2 mmHg 41.63 ± 4.73 48.92 ± 8.52 0.005
TSH (lIU/ml) 1.8 ± 0.85 1.4 ± 0.95 0.19
Total T3 (ng/ml) 1.2 ± 0.19 0.86 ± 0.25 <0.001
Total T4 (lg/dl) 8.56 ± 1.5 8.64 ± 1.7 0.88
Free T3 (pg/ml) 2.79 ± 0.45 2.09 ± 0.33 <0.001
Free T4 (ng/dl) 1.19 ± 0.18 1.15 ± 0.32 0.67
TT3/TT4 ratio 0.14 ± 0.08 0.1 ± 0.03 0.03
IL6 (pg/ml) 58.29 ± 51.64 69.45 ± 67.35 0.59
TNF-a (pg/ml) 5.21 ± 4.19 17.54 ± 15.48 0.006
r = 0.92, P<0.001
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Figure 1 Correlation between PaO2 and TT3/TT4 ratio in stable
COPD group.
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Figure 2 Correlation between PaO2 and total T3 in stable
COPD group.
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tions [11].
Systemic response to chronic disease in COPD patients
might cause hormonal imbalance which in turn affects the
severity of the disease. The severity of hypoxia and airway
obstruction in COPD patients is associated with impairment
of thyroid gland function and/or alterations in thyroid func-tion tests [8,14] The presence of thyroid dysfunction may vary
according to the phases of COPD.
The present study was performed to assess serum levels of
thyroid hormones and the inﬂammatory biomarkers IL-6,
TNF-a in COPD patients during stability and acute exacerba-
tion of the disease, and the relation between severity of COPD
and levels of thyroid hormones.
In the present study serum levels of total T3, free T3 and
TSH were signiﬁcantly decreased in the COPD exacerbation
group when compared to control subjects (p< 0.001,
p< 0.001, p= 0.002, respectively),and also when compared
to stable COPD patients (p= 0.001, p< 0.001, p< 0.001,
respectively), also serum levels of total T3 and free T3 were sig-
niﬁcantly decreased in stable COPD patients when compared
to control subjects (p= 0.01, p= 0.004, respectively) whereas
TSH levels did not differ signiﬁcantly between the two groups.
In our study the mean serum levels of thyroid hormones in
COPD patients were within normal limits, but mean serum to-
tal T3 and free T3 levels were slightly decreased below the low-
er limits of reference values in the COPD exacerbation group.
Also, in our study, regarding disease severity, there was a
statistically signiﬁcant decrease of serum total T3 and free
T3 levels (p< 0.001) in the severe COPD patient group than
that in the mild-to-moderate COPD patient group, but the dif-
ference was statistically non signiﬁcant as regards serum total
T4, free T4 and TSH levels between both groups.
Our results are in consistence with Karadag et al. [7] who
found that total T3 and free T3 levels were lower in the COPD
group than the control and the difference was more signiﬁcant
for free T3. Besides, there was signiﬁcant difference in TSH, to-
tal T3, free T3 levels and TT3/TT4 ratio between exacerbation,
stable, and control groups. They also revealed that hormonal
changes during follow-up after exacerbation period seemed
parallel to changes in PaO2 and PaCO2 and hormonal altera-
tions improved as the arterial blood gas values improved during
the recovery period of exacerbation. The increase in TSH levels
when hypoxia was improved and the disease become stable de-
notes delayed pituitary response to TRH secondary to hypoxia.
When they evaluated the relation between pulmonary func-
tion tests and thyroid hormones, they found out that serum to-
tal T3 was lower in severe COPD compared to moderate
COPD. Moreover, TSH, total T3, free T3 levels were lower
572 A. Shoukry et al.in patients with severe hypoxemia (PaO2 < 60 mmHg) when
compared to patients with milder hypoxia. They concluded
that the decrease in total T3, free T3 while T4 remains un-
changed in patients with severe airﬂow obstruction and pa-
tients in the exacerbation period with severe hypoxemia
indicating that hypoxemia and severity of COPD affect periph-
eral metabolism of thyroid hormones.
Madhuri et al. [15] found that mean level of free T3 was sig-
niﬁcantly lower among patients with acute exacerbation of
COPD due to having critical illness, and suggested that the
existence of non-thyroidal illness syndrome among those pa-
tients is more prevalent as compared to stable COPD and
healthy controls.
Akbas et al. [16] also found low free T3 and TSH levels in
critically ill COPD patients which increased when they recov-
ered from critical illness.
Dimopoulou et al. [4] have demonstrated that in stable
COPD patients, baseline thyroid hormones are within normal
limits; however, in severe COPD, a certain degree of thyroid
dysfunction was evident.
Semple et al. [17] measured serum total T3 and total T4 lev-
els in 16 patients with stable COPD having a mean FEV1 be-
low 40% of predicted and did not ﬁnd any difference among
hypercapnics, normocapnics and controls.
The same investigators [18] performed thyroid stimulation
tests in eight hypoxic, stable patients with severe COPD in a
subsequent study and found that their basal thyroid hormone
levels were normal, but two patients showed a delayed re-
sponse to TRH. They concluded that hypoxemia causes a min-
or change in the hypothalamic–pituitary–thyroid axis at the
hypothalamic–pituitary (central) level. However, the study
group is too small to generalize these ﬁndings.
Okutan et al. [19] found that thyroid hormone concentra-
tions were within normal limits in all COPD cases. But in con-
trary to our results, they found that free T3 concentration was
higher in stable COPD patients than the control group,.
Contrary to our results Uzun et al. [20] studied thyroid
function tests only in patients with acute exacerbation COPD
and found signiﬁcant difference according to the percentage of
cases with TSH less than minimum values and free T3 higher
than maximum values between COPD and control groups.
They demonstrated that both clinical and subclinical hyperthy-
roidism were higher in patients with COPD exacerbations than
cases without COPD. They suggest that severe airway obstruc-
tion and excessive respiratory muscle load affect thyroid hor-
mone levels in patients with COPD.
Coskun et al. [14] reported no signiﬁcant difference in
TSH and free T3 between the stable COPD group and
healthy controls but when classiﬁed according to severity, sig-
niﬁcant differences were observed between mild, moderate
and severe stable COPD patients with respect to free T3.
They also found that free T4 levels were signiﬁcantly higher
in the stable COPD group than healthy control whereas in
our study there were no statistically signiﬁcant differences
in Mean serum levels of total T4, free T4 between the studied
groups.
TT3/TT4 ratio has been proven to be a useful tool in studying
the peripheral conversion of thyroxine to themetabolically active
triiodothyronine in various disease states. In the present study
TT3/TT4 ratio was signiﬁcantly decreased in the COPD exacer-
bation group when compared to control subjects (p= 0.02)
and also when compared to stable COPD patients (p= 0.04),also TT3/TT4 ratio was signiﬁcantly decreased in the severe
COPD patient group than that in the mild-to-moderate
COPD patient group (p= 0.03), this is supported by Karadag
et al. [7] who found similar results in their study. Our results
revealed a signiﬁcant positive correlation between TT3/TT4
ratio and PaO2 in stable COPD patients (r= 0.92; p< 0.001)
which is supported by Dimopoulou et al. [4] who found the
same correlation but only in the severe stable COPD group.
In consistence with Karadag et al. [7], our results revealed a
signiﬁcant positive correlation between serum total T3 levels
and PaO2 in stable COPD patients (r= 0.76; p< 0.001).
In our study, with the exception of the previous correla-
tions, no other correlations were found between serum levels
of thyroid hormones (TSH, total T3. total T4 free T3 and free
T4) and FEV1% predicted, PaO2, PaCO2, in both stable and
exacerbation phase COPD patient groups which is supported
by many previous studies [15,20].
Gow et al. [8] investigated thyroid function in 20 patients
with exacerbation, having severe COPD (highest FEV1 40%
of predicted). They did not ﬁnd any correlation between arte-
rial blood gas measurement and thyroid hormone concentra-
tions in patients with COPD. Also, Banks and Cooper. [21]
measured thyroid hormones of 25 COPD patients with various
degrees of hypoxemia and hypercapnia and they found no rela-
tion between thyroid hormones and pH, PaO2 or PaCO2, these
results match our study results.
Whereas, contrary to our results, Coskun et al. [14] found a
negative correlation between FEV1 and free T4 in the stable
COPD group, and Okutan et al [19] demonstrated that there
was a negative correlation between pulmonary function tests,
PaO2 and free T3 in COPD patients.
Karadag et al. [7] found a positive correlation between
PaO2 and free T4 in the COPD exacerbation group and a
negative or inverse correlation between PaCO2 and TSH
in stable COPD patients that is why they consider hypercap-
nia may play a role in thyroid dysfunction besides
hypoxemia.
Several previous studies suggested that the underlying fac-
tors for alterations in thyroid hormones in COPD are hypox-
emia, hypercapnia and severe airway obstruction [7,18,19].
However, the alterations in thyroid hormones in COPD
might also be related to factors other than hypoxia and hyper-
capnia. TNF-a was demonstrated to be a mediator of several
diseases leading to hypothalamo–pituitary dysfunction. Sev-
eral previous studies investigated the effects of administering
TNF-a and IL-1b to experimental animals and humans and
conﬁrmed a possible role for them in the pathogenesis of
NTIS, and lowering of serum T3 [6,22,23].
Both cytokines also induce IL-6 production [4], which is
known to exert regulatory effects upon many endocrine sys-
tems, either independently, or acting with other cytokines.
Moreover elevated serum IL-6 concentrations are related to
alterations in circulating thyroid hormones in non-thyroidal
illness (NTI) secondary to various medical conditions [24,25].
Stouthard et al. [25] demonstrated that IV administration
of IL-6 induced an acute decrease in T3 and TSH. However,
during prolonged sc administration of IL-6, these effects
seemed to be transient. After 1 week of daily administration
of IL-6, thyroid hormones returned to baseline values.
Therefore they concluded that acute elevations of IL-6
may at least in part mediate the development of the NTIS,
whereas factors other than IL-6 contribute to the persistence
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chronic illness.
In the present study serum IL-6 and TNF-a concentrations
were signiﬁcantly higher in both stable (p= 0.02, p= 0.01,
respectively), and exacerbation phase (p= 0.007, p< 0.001,
respectively) COPD patient groups than control subjects, no
correlations were found between Serum levels of thyroid hor-
mones and TNF-a or IL-6 in both groups. Our results are in
agreement with Karadag et al. [7], But on the contrary, they
found that IL-6 was correlated with total T3 in the stable
COPD group.
Increased levels of IL-6 and TNF-a and other several pro-
inﬂammatory cytokines have been reported in the lungs and
circulation of patients with COPD in many studies [26–28].
Our study demonstrated that COPD is a systemic disease
that leads to alterations in serum levels of thyroid hormones
especially in severe COPD patients and during exacerbation
phases of COPD where NTIS is more evident; The pattern
of hormonal changes suggests that hypoxemia acts not only
at the central level of the hypothalamic–pituitary–thyroid axis,
but also interferes with the peripheral metabolism and turn-
over of thyroid hormones.
Considerable controversy still exists on whether NTIS in
COPD or other critical illness is a useful compensatory protec-
tive mechanism to counteract excessive catabolism and protein
breakdown and represents a physiologic adaptive response to
systemic illness by which it lowers tissue energy requirements;
or conversely is an unfavorable maladaptive state which in-
duces a damaging hypothyroid state at tissue level [7,29].
It is not clear if these patients with NTIS are biochemically
euthyroid or hypothyroid. A normal serum TSH in most NTIS
patients with low T3 may indicate that they are metabolically
euthyroid. On the other hand, several studies demonstrate
abnormalities in the synthesis, secretion, glycosylation, regula-
tion and/or effectiveness of TSH in NTI [13].
Moreover; other studies reported that the transient increase
in serum TSH during recovery from NTI suggests that TSH is
suppressed during the illness [30,31].
Overall, although patients with NTI may be euthyroid be-
cause of short duration of NTIS, those with a prolonged
NTI may be biochemically hypothyroid and may beneﬁt from
thyroid hormone replacement therapy [13]. However, studies
evaluating T3 replacement treatment in NTIS yielded either
no beneﬁt, or appreciable improvement [32–34].
Lastly, as there are signiﬁcant alterations of thyroid hor-
mones in COPD patients, they should not be evaluated for thy-
roid disease by assessment of thyroid functions during acute
exacerbation of COPD, and thyroid function alterations dur-
ing stable phase of the disease should be considered cautiously,
since thyroid function abnormalities in non-thyroidal illness
may mimic or mask biochemical abnormalities observed in
true thyroid disease.
Conclusion
There were signiﬁcant alterations in serum levels of thyroid
hormones in COPD especially in severe COPD patients and
during exacerbation phases of COPD where NTIS is more evi-
dent. There was a signiﬁcant decrease in serum total T3 and
free T3 levels in stable COPD patients and this decrease was
more signiﬁcantly evident with a superadded signiﬁcant de-crease in serum TSH levels during the exacerbation phase of
COPD. The hormonal alterations are especially related to
severity of the disease and hypoxemia. Serum IL-6 and
TNF-a levels were increased even in stable COPD and this rise
is magniﬁed with increased disease severity and during exacer-
bation phases of COPD.
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